inflammation and glp-1 Frontiers Frontiers | The role of
Description
Regulators are aware of the scale of patient exposure and the clinical sensitivity of these therapies
Farokhnia M, Tazare J, Pince CL, Bruns N 6th, Gray JC, Lo Re V 3rd, Fiellin DA, Kranzler HR, Koob GF, Justice AC, Vendruscolo LF, Rentsch CT, Leggio L
Contrave treated participants saw 5% weight loss compared to placebo at week 28 (55.6%
Wilson, Y
Feng, B
